price month
alzheim failur add pressur find
bace inhibitor failur surpris still disappoint
announc close phase trial bace inhibitor
verubecestat stop earli interim analysi suggest
would unlik drug show posit benefit/risk profil
trial drug previous fail trial patient mild-moder
alzheim diseas ad remain hope drug would
potenti show benefit given patient earlier cours
diseas remov verubecestat revenu model
incorpor chang along correspond reduct
sg lower target price new
target price blend dcf rel
valuat ep estim move
respect main risk call remain
disappoint data poor commerci execut around flagship
pressur increas find addit growth driver
remain bullish keytruda/immuno-oncolog franchis like
deal execut last year azn lynparza howev also clear
rest busi strong enough allow growth
see oncolog come today news
unexpect believ add increment pressur pursu
busi develop opportun bring addit growth driver
mid-lat stage pipelin agre manag recent
commentari deal driven innov would also stress
need larg enough move needl market cap
compani annual top line sale
 close
valuat metric
number share
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
merck co inc global health care compani deliv health
solut prescript medicin market
joint ventur oper segment
anim health consum allianc
price feb rate outperform target price analyst vamil divan
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
cash-flow financ activ
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
blue sky valuat base greater sale
keytruda januvia gardasil compar current base case
assumpt also model higher gross margin oper
margin base case assumpt blue sky valuat
base dcf driven wacc termin valu
grey sky valuat base lower sale
keytruda januvia gardasil compar current base case
assumpt also model lower gross margin oper
margin base assumpt grey sky valuat base
dcf driven wacc termin valu
compani mention price
